Adventrx Pharmaceuticals, Inc.
Gastrointestinal cancer drug developer records loss of $0.06 per share
Published in Oncology Business Week, December 18th, 2005
Adventrx reported a net loss of $3.5 million, or $0.06 per share, for the third quarter of 2005, compared with a net loss of $2.1 million, or $0.04 per share, for the third quarter of 2004.
"In the third quarter Adventrx experienced increased visibility to the investment community with the company's selection to the new Russell Microcap Index and with a $20 million private equity placement led by Carl Icahn," said Evan M. Levine, Adventrx president and chief executive officer. "We increased the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- AMDL, Inc.
Cancer test developer posts $0.03 per share loss - Adherex Technologies, Inc.
Study to define the prevalence of the molecular marker N-cadherin among a variety of tumor types - Aeterna Zentaris, Inc.
Cancer drug maker reports loss of $0.10 per share - Cell Genesys, Inc.
Favorable 2-year survival data from phase II clinical trial of GVAX vaccine for pancreatic cancer - Celsion Corp.
Cancer-focused company reports revenue of $3.2 million for quarter - Chungnam National University
Researchers publish new studies and findings in the area of proteomics - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
